Available neuroimaging methods such as computer tomography (CT) and magnetic resonance (MR) may detect structural abnormalities of the brain and contribute to differential diagnosis of parkinsonian syndromes. However, they often report normal fi ndings, especially in the early stages of the disease. Moreover, the severity of the disease lacks an imaging correlate 2 . Other neuroimaging methods such as single photon emission tomography (SPECT) and positron emission tomography (PET) identify biochemical changes in the nigrostriatal system and may detect a decrease in dopaminergic cells in the SN [3] [4] [5] [6] . However, these techniques are very expensive and not widely accessible.
Transcranial sonography (TCS) on the other hand, is a neuroimaging method with the ability to provide data on various brain structures in its B-mode [7] [8] [9] . In addition, transcranial color-coded duplex sonography is able to provide information on the intracranial arteries and veins as well 7, 8 . It is very quick, safe and non-invasive. The main limitation is that some patients do not have a suffi cient bone window 7, 8 . Although TCS resolution is inferior to MR, it can detect mesencephalic nuclei, assess the width of the third ventricle and the frontal horns of lateral ventricles. TCS could help in the diff erential diagnosis of PD and atypical parkinsonian syndromes (APS) in addition to clinical examination and other paraclinical, neuroimaging and genetic methods 7, 8 .
Transcranial sonography evaluation -methods
TCS evaluation of brain structures is realized through a transcranial (preauricular) acoustic window using transcranial duplex probe with the frequency about 1-4 MHz, dynamic range is 50-170 dB. Penetration depth is 14-16 cm with the imaging of the contralateral bone. TCS allows the depiction of brain structures in detail, e.g., mesencephalon with the zoom (Figure 1 ). Axial resolution of TCS evaluation is about 0.5-1.0 mm, lateral resolution is about 3.0 mm. The main limitation of TCS evaluation is insuffi cient transtemporal window, which is missing in 8-20 % of patients, depending on age and sex [8] [9] [10] [11] [12] . There is also a dependency on examiner's skills 7, 8, 13 . 
TCS evaluation substantia nigra in Parkinson's disease
In patients with PD, TCS is able to detect a hyperechogenic and enlarged area of the SN as a marker of striatonigral damage. It has a sensitivity of about 90 % and specifi city of about 90 % (ref. [14] [15] [16] [17] [18] ) -see Table 1 . The fi rst evaluations of the substantia nigra in PD patients were published in 1995. Becker et al. described SN in idiopathic PD as an echogenic nucleus inside the anechogenic butterfl y mesencephalon (Fig. 2) 6 the relationship between SN echogenicity and motor symptoms in an elderly population (56-70 years). They evaluated 330 patients and concluded that a hyperechogenic SN was often connected with bradykinesia, rigidity and higher age (over 60). We obtained very similar results in our study in a group of 202 patients with movement disorders. Hyperechogenic and enlarged area of SN were signifi cantly more frequent in patients with symmetrical bradykinesia and rigidity 20 . A subsequent study showed that a hyperechogenic SN is enlarged contralaterally to manifest parkinsonian symptoms 21 . However, in 8-10 % of healthy subjects, a hyperechogenic SN can be detected. Recent 18 F-DOPA in the sample studied. Although the examination of motor function was normal, it was suspected that there was a subclinical alteration of the striatonigral system 6, 10, 15, 21 . Walter et al. 11 investigated a group of patients with idiopathic PD and patients with non extrapyramidal symptoms. The results of the study show that bilaterally enlarged hyperechogenic SN is probably a marker of idiopathic PD. A hyperechogenic SN was detected in 45 % of the relatives of patients with idiopathic PD 22 . Moreover, in asymptomatic subjects with the Parkin mutation, a correlation was found between enlarged hyperechogenic SN and striatonigral alterations in PET studies 23 . Subsequent work detected a hyperechogenic SN in patients with olfactory dysfunction together with dopamine reuptake alteration on SPECT (123-FP-CIT) in 70 % of examined patients 23 .
Unipolar depression in Parkinson's disease
Depression and anxiety are very frequent symptoms in PD with a prevalence of about 40 %. They are probably related to the role of the brainstem in regulating mood and cognition. Becker et al. evaluated brainstem changes in patients with PD and unipolar depression using TCS 24 . These patients have signifi cantly decreased echogenicity of the brainstem raphé nucleus in comparison with non-depressive PD patients and a control group. There were also correlations with signal decrease on T 2 /diff usion-weighted images in MR studies 24 . Echogenicity inside the brainstem included nuclei and tracts, which connect mesencephalic structures with nuclei in the dorsocaudal (basal) limbic system. Morphologic alteration in the basal limbic system is one of the pathological factors in depression 26 .
Parkinsonian syndrome induced by neuroleptic therapy
Berg et al. 27 measured area and echogenicity of SN in patients with a parkinsonian syndrome induced by neuroleptic therapy use in psychiatric indications in a retrospective study. In patients with a neuroleptic-induced parkinsonian syndrome, SN was signifi cantly enlarged (0.19 cm 2 on the right side and 0.21 cm 2 on the left side), compared to neuroleptic-treated patients without parkinsonian symptoms (0.12 cm 2 on the right side and 0.11 cm 2 on the left side). The pathological mechanism underlying expression of parkinsonian symptoms in these patients is probably neuroleptic blockade of dopaminergic receptors in the basal ganglia. According to a published hypothesis, it could manifest more frequently in patients with subclinical injury to the basal ganglia. The size of hyperechogenic SN is associated with severity of extrapyramidal symptoms 27 .
Echogenicity of substantia nigra and iron metabolism
The exact reason for the hyperechogenicity and enlargement of SN in PD and parkinsonian syndromes is still unknown. Post-mortem assessment demonstrate that echogenicity of SN could relate to increased iron deposits in the basal ganglia 15 . Berg et al. in their experimental study attempted to confi rm this hypothesis. The rat brain was evaluated using TCS after stereotactic injection of different concentrations of iron or ferritin, zinc and 6-OHDA (6-OH-dopamine) together with desferrioxamine. The iron content in the SN was assessed using spectroscopy and the echogenicity of SN was measured as well. Increasing iron content increased the echogenicity of SN 14 . It is possible that a hyperechogenic and enlarged SN in atypical syndromes like MSA (multiple system atrophy) and VP (vascular parkinsonism) is caused by this mechanism. Reasons for development of variable iron metabolism impairments in these parkinsonian syndromes will be the topic of further research 14 . Neuronal degeneration in the SN region could also be induced by toxic exposure to pesticides, heavy metals, by basal ganglia injury or by oxidative damage 5, 14 . The authors speculate about the possible contribution of pure SN atrophy 19 . Iron participates in various biological processes. It is an essential cofactor of many enzymes. Iron supports the transport of oxygen in hemoglobin and plays the main role in many oxidative and reduction processes as a cofactor. On the other hand, free iron in the human body is toxic given its ability to form free radicals. Ferrous ion Fe ++ can generate the highly toxic hydroxyl and superoxide free radicals or molecular oxygen 28 . Ferritin is a storage protein of iron in the tissues and is important for blood formation. It is present in the normal axon. Recent studies reported on two cases of L-ferritin gene mutations. These mutations are associated with degeneration of the basal ganglia and occur in families. The disorder is termed hereditary ferritinopathy. The fi rst published work failed to confi rm more frequent occurrence of these mutations in patients with PD or increased SN echogenicity 29 . Ferroxidase ceruloplasmin (Cp) is involved in iron metabolism. It is produced by the spleen and secreted into the blood. By oxidizing the ferrous Fe ++ form of iron to the ferric Fe +++ form, Cp promotes iron loading onto transferrin. In this way, Cp is an eff ective antioxidant and prevents oxidative damage to proteins, lipids and DNA. Cp is also produced by astrocytes in the brain, cerebellum, retina and epithelial cells of the choroid plexus. Astrocytes produce a special form of ceruloplasmin, which is connected to the membrane by glycosylphosphatidylinositol (GPI). This form of Cp plays a very important role in iron homeostasis and antioxidant processes in the brain.
Studies of patients with aceruloplasminemia, who have hereditary ceruloplasmin gene mutation, show that in these patients, iron accumulates in various organs, e.g., liver and brain. Iron deposits lead to neurodegeneration and expression of neurological symptoms -motor incoordination, parkinsonism, dementia and other medical disorders, such as diabetes mellitus.
Hochstrasser et al. 30 examined mutation of Cp gen in 176 PD patients. D554E with I63T mutation was found in PD patients with hyperechogenic SN, whereas R793H mutation was also detected in the normal population with a hyperechogenic SN. Furthermore, this study shows a correlation of Cp and formation of Lewy bodies. Pilot Transcranial sonography in movement disorders study shows the possibility of correlation of Cp ferroxidase in blood and hyperechogenic SN 31 . Neuromelanin is accumulated in SN pigmented neurons with normal aging. Neuromelanin plays an important protective role in inactivation of Fe ++ and reduced formation of free hydroxyl radicals, which otherwise contribute to oxidative stress and neuronal death. Neuromelanin could interact with many heavy metal ions, e.g., zinc, copper, manganese or cadmium. In the course of Parkinson's disease and related syndromes, the concentration of iron in the SN increases by 30-35 % (ref. 32 ). In contrast, neuromelanin in SN is decreased in PD patients. This decrease could be caused by reduction of neuromelanin production or its higher degradation or higher sensitivity of pigmented neurons to neurotoxins 53 . Zecca et al. in post-mortem studies detected increased content of iron in the hyperechogenic SN in 40 PD patients. A negative correlation was found between hyperechogenic SN and neuromelanin content of SN 33, 34 . Although the exact mechanism by which iron gets redistributed in various region of the brain is poorly understood, it is known that brain cells in certain areas of the brain have variable ability of to accumulate iron. It has not been clarifi ed whether this accumulation is caused by primary accumulation of iron compounds in microglia and macrophages or by iron accumulation in neurons 28 .
TCS evaluation in other movement disorders
Studies published so far demonstrate that changes in SN echogenicity detected by TCS are not specifi c for PD, but they are also more frequent in other movement disorders than in a healthy population 7, 8, 18 . In addition to the SN structure, TCS can be used to evaluate changes in others structures -e.g., the lenticular nucleus, caudate nucleus, cerebellum, width of the third ventricle or the frontal horn of lateral ventricles (Table 2) .
Multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration
Enlarged and hyperechogenic SN on TCS examination is not specifi c to PD. In patients with multiple system atrophy (MSA), increased echogenicity and area of SN is also seen. Behnke et al found hyperechogenic SN in 25 % patients with MSA and medium echogenicity in another 37.5 % (ref. 35, 36 ). In our group of patients with MSA, hyperechogenic SN (> grade III) was detected in 42.9 % and medium echogenic (grade III) in 14.2 % patients. Enlarged area of SN ≥ 0.25 cm 2 was found in 50 % patients 19, 20 . Patients were selected using Quinn's criteria 37, 38 . Between 72 % and 82 % of patients with MSA also have a hyperechogenic lenticular nucleus 35, 36 . Very similar fi ndings were described in patients with progressive supranuclear palsy (PSP) 7, 39 . Smaller studies reported that echogenicity of SN and lenticular nucleus could distinguish PN from MSA and PSP in more than 90 % (ref. 7, 35, 36 ). Signal decrease in globus pallidus on T 2 -weighed MR images also correlates with a hyperechogenic LN on TCS 39 . Measurement of third ventricle could be used in diff erential diagnosis between MSA and PSP. In the majority of the patients with PSP, the third ventricle was dilated by over 10 mm. Using this measurement, we could distinguish also PSP and corticobasal degeneration (CDB) in 90 % (ref. 39 ), especially if combined with a bilaterally enlarged hyperechogenic SN, which occurs in 90 % patients with CBD 39 .
Essential tremor
Diff erentiation between PD and essential tremor (ET) based on clinical examination can be diffi cult at the beginning of the disease 40 . Niehaus et al. 41 in a pilot study demonstrate that echogenicity of SN in ET is signifi cantly lower than in patients with PD and is very similar to the fi ndings in a healthy population. Hyperechogenic enlarged SN was detected in 28 (93 %) of 30 patients with tremor-dominant PD, but only in 2 patients (10 % 
Wilson's disease
Wilson's disease is an autosomal recessive hereditary disease in which copper becomes abnormally stored especially in hepatic tissue, cornea and basal ganglia. Hepatal, neurological and psychiatric symptoms may manifest. In 2005, Walter et al. investigated 21 patients with Wilson's disease, out of whom 18 patients had neurological symptoms and 3 patients were neurological symptom free. Hyperechogenic SN was detected in 10/21 patients. This fi nding did not correlate with the expression and severity of neurological symptoms. In 19 patients, they detected hyperechogenic LN, in 12 out of these patients this pathology was also visible on MRI. A hyperechogenic thalamus was detected in 9 patients, enlargement of the third ventricle in 4 patients, enlargement of frontal horns of lateral ventricles in 5 patients. Hyperechogenic LN and thalamus correlated with expression and disease severity 43 . The results of the pilot studies suggest the ability of TCS to detect accumulation of copper in the basal ganglia preclinically but the results must be confi rmed in larger patient population 43 .
Vascular parkinsonism
Tsai et al. (2007) studied hyperechogenic SN in 80 patients with PD in comparison with 30 patients with vascular parkinsonism (VP) and 60 normal controls. A hyperechogenic SN was present in 84 % of PD patients, in 20 % of VP patients and in 5 % of controls. 66.7 % of VP patients had evident vascular changes on TCS evaluation and their pulsatility index was signifi cantly higher than in PD patients and controls. There were no signifi cant diff erences in fl ow velocities between the VP and PD patients and controls 44 . In our pilot work 19 , we evaluated 11 patients with VP using TCS. Patients were classifi ed according to the vascular rating scale for the diagnosis of vascular parkinsonism 45, 46 . Echogenicity and area of SN were higher in comparison with healthy population, but the results did not reach statistical signifi cance. Hyperechogenic SN was detected in 18.2 % of cases and medium echogenicity in 45.4 %.
Dementia with Lewy bodies
Idiopathic PD and dementia with Lewy bodies (DLBD) are both characterized neuropathologically by the presence of Lewy bodies in various parts of the brain, especially in the brainstem, diencephalon, basal ganglia and neocortex. The presence of Lewy bodies is the main pathological substrate underlying cognitive dysfunction in PD and DLBD. Neuroimaging methods such as CT, MR and PET are not able to distinguish idiopathic PD from DLBD.
Walter et al. studied echogenicity of SN in patients with DLBD, Parkinson's disease patients with dementia (PDD) and PD patients without dementia. Hyperechogenic enlarged SN was detected at least on one side in 97 % patients with DLBD, 97 % patients with PDD and 94 % patients with PD without dementia. Bilateral hyperechogenic SN was detected mainly in DLBD in 80 %. Only one third of PD patients had bilateral fi ndings of hyperechogenic SN. In PND patients these fi ndings were associated with the youngest age. An asymmetry index was ≥ 1.15.
PDD and DLBD patients could be discriminated by a combination of hyperechogenic enlarged SN, asymmetry index and onset age with a sensitivity of 96 % and specifi city of 80 %, positive predictive value was 93 %. In patients with DLBD and PDD the width of the third ventricle and frontal horn was signifi cantly larger than for PD patients without dementia. This enlargement correlated with UPDRS scale in PDD 47 .
Huntington's disease
Huntington's chorea is a genetically caused neurodegenerative disease characterized by expansion of CAG triplets which leads to clinical symptoms. Postert et al. 48 published the fi rst results of TCS evaluation of patients with Huntington's disease in 1999. In 40 % of their patients, a hyperechogenic SN (in 27 %) or caudate nucleus (in 13 %) was detected. No changes in the echogenicity of the thalamus or LN there were found. It is suspected that hyperechogenicity of the caudate nucleus is caused by gliosis or increase in metal concentration. Neuropathological studies have confi rmed higher levels of iron and lower levels of ferritin in the caudate nucleus. Increase in copper concentration is probably responsible for the hyperechogenic SN 49 .
Spinocerebellar ataxia
The results of a recent TCS study 50 confirm that patients with genetically-proven spinocerebellar ataxia subtype 3 (SCA3) show hyperechogenicity of various brain structures, as do subtypes SCA1 and SCA2. Hyperechogenic white matter of the cerebellum was detected in 57 %, hyperechogenic dentate nucleus in 54 %, hyperechogenic SN in 40 %, hyperechogenic putamen in 40 % and hyperechogenic pallidum in 40 % patients. These were signifi cantly higher than in the healthy population (p < 0.05). Moreover, cerebellar atrophy and enlargement of the fourth ventricle were detected in all patients with SCA3. Finally, the width of the third ventricle and the lateral ventricle were signifi cantly larger than in the control group 51 .
Dystonia
Dystonia is characterized by involuntary prolonged muscle contractions that distort the body into typical postures 52, 53 . The pathogenesis of idiopathic dystonia and their origin is still unknown. It is known that the basal ganglia are the generator of dystonic movement. One of the pathological mechanisms described in the patients with idiopathic dystonia is increase in copper content in LN. Accumulation of copper probably causes disturbance of neuronal transfer from LN to motor cortex. The reason for copper metabolism impairment is unclear. Menkeson protein is the copper-transporting membrane ATP-ase and transports copper from cells outside. The results indicate that reduction of Menkeson protein gives rise to copper metabolism impairment and accumulation of copper in brain cells.
The fi rst evaluation of dystonic patients using TCS were published by Naumann et al. in 1996 (ref. 52 ). Subsequent studies 53 demonstrated that hyperechogenic LN is present in patients with torticollis or dystonic writer's cramp on the contralateral side of rotation of the head or aff ected hand. This echogenicity is higher than in a normal population 53 . A hyperechogenic SN was found in patients with facial dystonia only in 31 % (ref. 52 ). In practice, hyperechogenic LN could support the diagnosis of idiopathic dystonia and diff erentiate tardive dyskinesia and psychogenic dystonia.
Restless leg syndrome
The majority of patients with restless leg syndrome (RLS) have normal neurological fi ndings on clinical examination and routine neuroimaging 54, 55 . MRI studies which are able to quantify the concentration of iron in the brain of patients with RLS (according to criteria from the year 2003) 55 , detected decrease of iron concentration in SN and putamen 56 . Two TCS studies reported a reduction in SN echogenicity in 82 % of patients with idiopathic RLS and 40 % with the secondary RLS. The detectable area 56, 57 of SN was less than 0.1 cm 2 . In both groups, the same pathological mechanism is suggested -iron homeostasis disorder in the brain 56, 57 .
Reproducibility of the sonographic evaluation
Many studies have shown that TCS is a reliable method with high specifi city and sensitivity in the diagnosis of PD [14] [15] [16] [17] [18] . Correlations of SN evaluation were statistically signifi cant (r = 0.8, Cohen's kappa coeffi cient 0.83) 6, 8 . Our study focused on the inter-reader reproducibility of TCS evaluation and correlations in the assessment of Transcranial sonography in movement disorders substantia nigra (SN) echogenicity and area measurement by physician-sonographer, sonographic lab assistant and physician without sonographic experience. Correlations between readers (intra-reader and inter-reader) and correlation between investigators (intra-investigator and interinvestigator) were assessed. Correlations between readers were r = 0.55-0.82 for evaluation of echogenicity and r = 0.31-0.74 for evaluation of SN area (p < 0.05).
Intra -reader correlations were signifi cant only in an experienced sonographer (r = 0.85-0.96 for echogenicity and r = 0.51-0.69 for area SN, p < 0.001).
Also all correlations between investigators (intra-investigator and inter-investigator) were signifi cant as well for evaluation of area (r = 0.69-0.88 and r = 0.5-0.61), as well as echogenicity SN (r = 0.64-0.92 and r = 0.51-0.69, p < 0.05). All 3 readers identifi ed the same 15 patients with SN echogenicity III or more. It is known that semiquantitative TCS evaluation of area and echogenicity of SN depends on sonographer experience. Only an experienced sonographer is able to achieve reliable results with statistically signifi cant correlations. Correlations between sonographic lab assistant and physician without sonographic experience were low 13 . CONCLUSION TCS is a very quick, non invasive and inexpensive examination method. It could be helpful in the diff erential diagnosis of movement disorders. The results depend on the examiner experience and quality of transtemporal bone window. Using TCS, we could also detect structural involvement of the nigrostriatal system in preclinical stages of other neurodegenerative disorders. Available pilot results of these observations are presently being replicated in wider patient populations. ABREVIATIONS APS -atypical parkinsonian syndromes CBD -corticobasal degeneration MSA -multiple system atrophy NPV -negative predictive value PD -Parkinson's disease PPV -positive predictive value PSP -progressive supranuclear palsy SD -standard deviation Se -sensitivity Sp -specifi city TCS -transcranial sonography UPDRS -Unifi ed Parkinson's Disease Rating Scale
